All In Biotech

Drug Trial Radar · NCT03232073

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

Multicenter, Non-comparative Extension of Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

877

Actual

Start

Jul 5, 2017

Primary completion

Jan 16, 2024

Study completion Jan 16, 2024

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.

Conditions

  • Multiple Sclerosis

Interventions

  • PonesimodDrug

    Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Confirmed Relapse Rate (ARR)Time frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  2. Time From Core Study Randomization to First Confirmed RelapseTime frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  3. Time to First 12-week Confirmed Disability Accumulation (CDA)Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  4. Time to First 24-week Confirmed Disability Accumulation (CDA)Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  5. Percentage of Participants With Absence of RelapsesTime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  6. Change From Baseline in Expanded Disability Status Scale (EDSS)Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  7. Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of StudyTime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  8. Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of StudyTime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  9. Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
  10. Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRITime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  11. Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRITime frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
  12. Cumulative Number of New or Enlarging T2 Lesions Measured by MRITime frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
  13. Change From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
  14. Number of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
  15. Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
  16. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
  17. Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) AbnormalitiesTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
  18. Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart RateTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  19. Actual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcFTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  20. Change in Heart Rate (HR) From Baseline up to End of Study TreatmentTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  21. Change in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study TreatmentTime frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  22. Absolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) ValuesTime frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  23. Percent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  24. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
  25. Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
  26. Number of Participants With AE Leading to Premature Discontinuation of Study TreatmentTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
  27. Number of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVCTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
  28. Number of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From BaselineTime frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
  29. Number of Participants With a Decrease of >=200 mL or >=12% in FEV1 or FVC From Baseline to EOTTime frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  30. Change in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  31. Change in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
  32. Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From BaselineTime frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
  33. Change in DL[CO] (% Predicted) From Baseline to EOTTime frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
  34. Change in DL[CO] (% Predicted) From Baseline to EOSTime frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months

Locations

148 sites in 28 countries. Site status is shown where the registry gives one.

  • The Research Center of Southern California, LLC

    Carlsbad, California

  • The Neurology Group

    Pomona, California

  • Mountain View Clinical Research

    Denver, Colorado

  • Neurology Associates of Ormond Beach

    Ormond Beach, Florida

  • University of South Florida

    Tampa, Florida

  • Josephson Wallack Munshower Neurology, PC

    Indianapolis, Indiana

  • Raleigh Neurology Associates

    Raleigh, North Carolina

  • Ohio Health

    Columbus, Ohio

  • Advanced Neurosciences Institute

    Franklin, Tennessee

  • Grodno University Hospital

    Grodno, Belarus

  • Minsk City Clinical Hospital 5

    Minsk, Belarus

  • Republican Scientific Clinical Centre

    Minsk, Belarus

  • Vitebsk Regional Diagnostic Center

    Vitebsk, Belarus

  • Vitebsk Regional Clinical Hospital

    Vitebsk, Belarus

  • University Clinicl Center Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • UMHAT Sveti Georgi

    Plovdiv, Bulgaria

  • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum

    Sofia, Bulgaria

  • Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead

    Sofia, Bulgaria

  • Acibadem City Clinic Tokuda Hospital

    Sofia, Bulgaria

  • St Ivan Rilski University Multiprofile Hospital For Active Treatment

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment Alexandrovska EAD

    Sofia, Bulgaria

  • Military Medical Academy Multiprofile Hospital for Active Treatment Sofia

    Sofia, Bulgaria

  • University of Alberta

    Edmonton, Alberta, Canada

  • Royal Jubilee Hospital

    Victoria, British Columbia, Canada

  • Ottawa Hospital

    Ottawa, Ontario, Canada

  • Recherche Sepmus Inc.

    Greenfield Park, Quebec, Canada

  • Ch Osijek

    Osijek, Croatia

  • University Hospital Center Zagreb

    Zagreb, Croatia

  • Fakultní nemocnici Brno

    Brno, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Nemocnice Jihlava

    Jihlava, Czechia

  • Fakultni Nemocnice Ostrava

    Ostrava-Poruba, Czechia

  • Pardubicka krajska nemocnice a s

    Pardubice, Czechia

  • Vseobecna Fakultní Nemocnice

    Prague, Czechia

  • FN Motol

    Prague, Czechia

  • Krajska zdravotni, a.s. - Nemocnice Teplice, o.z.

    Teplice, Czechia

  • Suomen Terveystalo Tampere

    Tampere, Finland

  • Mehilainen NEO

    Turku, Finland

  • Hopital Pellegrin CHU Bordeaux

    Bordeaux, France

  • CHU Clermont-Ferrand - Hopital Gabriel Montpied

    Clermont-Ferrand, France

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.